Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $70 to $78.
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $70 to $78.